Revvity Inc vs Schwab US Large Cap Growth ETF — how do they compare? Revvity Inc trades at $154.82 (market cap $16.98B), while Schwab US Large Cap Growth ETF trades at $36.72 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 3.8× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| RVTY | SCHG | |
|---|---|---|
Market Cap | $16.98B | $65.01B |
Volume | 1,456,900 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $157.36 | $36.93 |
52-Week Low | $82.26 | $28.10 |
Typical Hold Time | 12 Days | 50 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.60, down 0.73% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent position reduction by Corient Private Wealth. Recent news highlights SCHG's low-cost advantage and growth-focused strategy, though concentration in top holdings presents both opportunity and risk.
The outlook for SCHG remains positive given its exposure to large-cap growth stocks and cost efficiency, though investors should monitor concentration risks in top holdings and broader market volatility. The ETF's historical performance suggests potential for long-term growth, but current valuation levels warrant careful assessment relative to alternatives like GARP strategies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →